Loading stock data…
SIBN
$13.21+0.82 (+6.62%)
Market ClosedLast close May 1
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
SI-BONE, Inc. in the Healthcare sector is trading at $13.21. The stock is currently near its 52-week low of $11.80, remaining 17.7% below its 200-day moving average. Technical signals show neutral RSI of 43 and bearish MACD signal, explaining why SIBN maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 43) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$13.21
Potential Upside
5%
Whystock Fair Value$13.87
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented tita...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$613.66M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.77
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-10.65%
Volume
Today's trading volume
1.01M
Recent News
Jim Cramer on SI-BONE, Inc.: “We’re Not Going to Buy the Money Losers”
SI-BONE, Inc. (NASDAQ:SIBN) is one of the stocks Jim Cramer answered questions about. Inquiring about the stock, a caller mentioned that it has declined around 30% since they last asked about it in January. In response, Cramer said: Gee, I don’t know. That’s, whoa, they’re losing too much money. We’re in a tough tape. We’re […]
SI-BONE, Inc. Q4 2025 Earnings Call Summary
Moby summary of SI-BONE, Inc.'s Q4 2025 earnings call
Smith+Nephew, SI-BONE partner to distribute iFuse TORQ portfolio
The iFuse TORQ portfolio includes the iFuse TORQ TNT and iFuse TORQ implants.
SI-BONE Inc (SIBN) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic Partnerships ...
SI-BONE Inc (SIBN) reports robust revenue growth and strategic initiatives, setting the stage for continued expansion in 2026 despite anticipated challenges.
Si-Bone (SIBN) Reports Q4 Loss, Tops Revenue Estimates
Si-Bone (SIBN) delivered earnings and revenue surprises of +69.23% and +0.09%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?